Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a high impact on the comfort of those who are affected and long-term treated with corticosteroids with limited efficacy and a high prevalence of relapses. Because of the limited effectiveness of these treatments, new strategies for recovery from AD lesions are continually being explored. In this article, we describe the gut microbiome changes achieved in a recently published clinical trial with the probiotic formulation Bifidobacterium animalis subsp. lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lacticaseibacillus casei CECT 9104 (formerly Lactobacillus casei CECT 9104), showing a significant improvement in SCORAD (scoring atopic dermatitis) index in children (4–17 years) with AD (Clinicaltrials.gov identifier: NCT02585986). The present gut microbiome post hoc study showed no significant changes in diversity (Shannon and Simpson indexes) after probiotic consumption. In the probiotic group, genera Bacteroides, Ruminococcus, and Bifidobacterium significantly increased their levels while Faecalibacterium decreased, compared to the placebo group. Faecalibacterium showed the highest presence and significant positive correlation with AD severity (SCORAD index), whereas Abyssivirga, Bifidobacterium, and Lactococcus were inversely correlated. The results suggest that the consumption of the probiotic formulation here assayed modulates the gut microbiome with significant changes in genera Bacteroides and Faecalibacterium. In turn, the improvement in SCORAD correlates with a decrease in Faecalibacterium and an increase in Bifidobacterium, among others.
Background and Clinical Significance: Cutaneous toxicity is a frequent adverse event of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and may impair quality of life and adherence in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR), derived from a routine blood count, is an inexpensive inflammatory marker associated with prognosis in this setting, but its relationship with TKI-induced cutaneous toxicity is largely unexplored. The primary objective of this exploratory case series was to describe the frequency, timing and clinical pattern of cutaneous toxicity during the first six months of TKI therapy. As a secondary, hypothesis-generating aim, we explored whether baseline NLR differed between patients who developed cutaneous toxicity and those who did not. Case Presentation: We retrospectively reviewed ten patients with EGFR-mutated NSCLC treated with erlotinib, afatinib or osimertinib at a single Spanish regional hospital (2023–2025). Median age was 70 years (IQR 61.75–77.50); (60%) were women, (80%) had adenocarcinoma, exon 19 deletion was the most frequent alteration (60%), and (70%) received osimertinib. Cutaneous toxicity (CTCAE v5.0) occurred in five patients at three months and seven at six months, mostly grade 1; acneiform eruption predominated early and paronychia later. Median baseline NLR was numerically lower in patients with toxicity at six months (1.69 vs 2.75; p = 0.305), with no relevant difference at three months. Conclusions: In this small, single-centre, exploratory case series, cutaneous toxicity was common during the first six months of EGFR tyrosine kinase inhibitor therapy. Although patients who developed toxicity by six months had a numerically lower baseline NLR, this difference was not statistically significant and should be interpreted only as hypothesis-generating.